Tech Company Financing Transactions
Edge Therapeutics Funding Round
Edge Therapeutics, operating out of Berkeley Heights, received $56 million in funding from Venrock, BioMed Ventures and Janus Capital.
Transaction Overview
Company Name
Announced On
4/9/2015
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series C
Investors
Venrock (Lead Investor) (Anders Hove)
Sofinnova Ventures (James Healy)
Proceeds Purpose
Edge expects to use part of the proceeds from these financings to complete its Phase 1/2 NEWTON study and prepare for a Phase 3 pivotal study for its lead product candidate, EG-1962, which is designed to improve patient outcome following an aneurysmal subarachnoid hemorrhage (aSAH), also known as a ruptured brain aneurysm.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
300 Connell Dr. 4000
Berkeley Heights, NJ 07922
USA
Berkeley Heights, NJ 07922
USA
Phone
Undisclosed
Website
Email Address
Overview
Edge Therapeutics, a pharmaceutical company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frank Bedu-Addo
Chief Financial Officer
Andrew Saik
Chief Medical Officer
Lauren Wood
Chief Scientific Officer
Gregory Conn
VP - Administration
Bert Marchio
VP - General Counsel
Brad Middlekauff
VP - Operations
Alpaslan Yaman
VP - Regulatory Affairs
Alyssa Wyant
Browse more venture capital transactions:
Prev: 4/9/2015: Kidizen venture capital transaction
Next: 4/9/2015: Niara venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs